Because cancer is devastating for all our lives. We have a vested interest in improving patient care and outcomes and are committed to removing diagnostic and monitoring complexity and reducing unnecessary cancer-related costs.
A Vision to Transform Healthcare through AI
Our vision is more than an idea. It's a tangible roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform.
This solution aids critical decision support during clinical diagnosis and monitoring to:
Operating at the Intersection of Computer Science and Healthcare
In 2018, AIxMed's founders blended their divergent, respective backgrounds to break through the ineffective traditional cytology status quo. Samuel Chen brings AI technology ingenuity and leadership experience from ASUS and Compal. Dr. Tien-Jen Liu offers medical expertise as a trained physician and serial medtech entrepreneur.
Their combined diversity of thought will make a meaningful impact in healthcare, with intuitive commercialized tools to simplify clinical workflows and richly strengthen the quality of healthcare.
About Our AI Technology
Top-Notch Technical Team
A unified and multi-disciplinary approach guides our product development to aid in cancer detection and management. Our technical team includes a national software development champion and an international math Olympiad gold medalist. We also placed in the top 1% among 4000 teams at the 2018 Kaggle (Google) Data Science Bowl (data provided by Broad Institute).
Chief Executive Officer, President & Co-Founder
Bringing over 25 years of software development experience to the team, Samuel Chen is the president and CEO of AIxMed. He was the Vice President of Software Development at Trend Micro and helped establish the company as one of the top three information security companies in the world and Taiwan’s #1 software company. Additionally, Mr. Chen held executive leadership roles at ASUSTek and Compal and founded the Compal AI Lab. Mr. Chen graduated from National Chiao-Tung University and attained a Master’s of Science degree in computer science from the University of Southern California.
Chief Operating Officer & Co-Founder
Tien-Jen Liu, MD, is an experienced attending physician with a proven history in the biotechnology industry. Dr. Liu is skilled in clinical research, medical device development, clinical study, and business development. He is also the director of the biomedical innovation program at a medical university.
SVP Business Development
Steph Hess is an experienced business development professional bringing two decades of IVD and life science experience to the team in both Product and Business Development. He has consulted for dozens of start-up companies and helped introduce multiple products to the market. Mr. Hess was previously VP Global Business Development at Invetech and VP Global Sales and Marketing at IDEX Health and Science. Steph obtained an Engineering Degree from Rutgers University and a Master’s of Science degree in Management from WPI.
Dr. Crothers is both a highly decorated U.S. Army veteran and one of the country’s most renowned Cytopathologists. Prior to joining AIxMed, she served as Senior (Consultant) Pathologist at The Joint Pathology Center (JPC), known as the premier pathology reference center for the U.S. federal government. Dr. Crothers is board-certified in anatomic and clinical pathology as well as Cytopathology, and over the course of her career, she has received numerous professional, military, and academic honors and awards. She has served as President and Executive Board Member of the American Society of Cytopathology (ASC) and the Chair of the Cytopathology Committee at the College of American Pathologists (CAP).
Accomplished Advisory Board
Dr. HJ Chang
Dr. Judy Chou
Ms. Laura Housman
Mr. Shawn Marcell
Dr. Liron Pantanowitz
Dr. Yuh-Geng Tsay
Dr. Vincent S. Tseng
Dr. Christopher VandenBussche
Ms. Fran White